Vera Therapeutics gains after kidney disease drug meets goals in confirmatory trial

Vera Therapeutics

15/09/2026 12:03

** Shares of Vera Therapeutics VERA.O rise 11.6% to $38 premarket
** Company says its drug Trutakna has met all goals in a late-stage confirmatory trial of 428 adults with immunoglobulin A nephropathy, which can lead to kidney failure
** Drug largely stabilized kidney function and cut the risk of disease progression by 76% vs placebo over two years - VERA 
** No Trutakna patients experienced long-term dialysis, kidney transplantation or death through two years, compared to eight patients on placebo - VERA
** Safety was broadly similar to placebo, with no new concerns reported
** Company plans to seek full U.S. approval in Q4 2026 after the drug received accelerated approval in July
** As of last close, VERA down 32.8% YTD

 (Reporting by Kunal Das in Bengaluru)
 ((Kunal.Das2@thomsonreuters.com;))